Clinical efficacy and safety of Shenfu injection in the treatment of leukopenia induced by chemotherapy after surgery of breast cancer
10.13699/j.cnki.1001-6821.2015.24.004
- VernacularTitle:参附注射液治疗乳腺癌术后化疗致白细胞减少的临床疗效及安全性评价
- Author:
Li-Na LIU
1
;
Kan QIU
;
Bao-Gui ZHONG
;
Shu-Shan YANG
;
Zhen-Dong ZHI
;
Chang-Heng YIN
Author Information
1. 衡水市人民医院药剂科
- Keywords:
breast cancer;
Shenfu injection;
induced leucopenia;
docetaxel;
epirubicin;
cyclophosphamide;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(24):2384-2386
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of Shenfu injection in the treatment of leukopenia induced by chemotherapy docetaxel, epirubicin and cyclophosphamide adjuvant chemotherapy ( TEC chemotherapy) after surgery of breast cancer.Methods A total of 106 patients with breast cancer were randomly divided into control group ( n=53 ) and treatment group ( n =53 ) .Control group was re-ceived 75 mg? m-2 docetaxel, intravenous infusion on day 1 +50 mg? m-2 epirubicin, intravenous infusion on day 1 +500 mg? m-2 cy-clophosphamide, intravenous infusion on day 1, 3 weeks for a course. Treatment group was given 50 mL Shenfu injection added 500 mL of 5%glucose intravenous infusion and plus the treatment of control group, 1 to 10 days for a course.Patients of two groups were received 2 courses of treatment.The clinical efficacy, the incidence of leukopenia, white blood cell count to improve the rate and quality of life before and after treatment, and adverse drug reactions in two groups were compared.Results After treatment, total effective rate in treatment group was significantly higher than that in control group (84.91%vs 69.81%, P<0.05).After treatment 7,10 d, leukopenia rates in treatment group were 9.43%and 11.32%, significantly lower than 37.74%and 30.19%in control group (P<0.05).After treatment, the white blood cell count in the two groups all decreased than those before treatment, and the degree of decline in treatment group was higher than that in control group (P<0.05).After treatment, the rate of improvement of quality of life in treatment group was significantly higher than that in control group (88.68%vs 54.72%, P<0.05).The incidence of adverse drug reactions in treatment group was significantly lower than that in control group ( P<0.05).Conclusion Shenfu injection has a definitive clinical efficacy for the treatment of chemotherapy-induced leukopenia, which may improve immune function and the quality of life, worthy of further promotion in clinical practice.
